Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tissue is the issue and tissue competition. Re‐biopsy for mutation T790: where and why?

18 Jan 2017

Abstract excerpt

Lung cancer is still the leading cause of death among all cancers. During the last 15 years, pharmacogenomics of lung cancer have established targeted therapy with tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) positive patients in adenocarcinoma or mixed adenosquamus lung cancer patients. However; while novel drugs are released in the market, at the same time novel mutations are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28101783
DOI: 10.1186/s40169-017-0135-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tissue is the issue and tissue competition. Re‐biopsy for mutation T790: where and why?PMID 28101783Read ↗

Tissue Is the Issue for Diagnosis of EGFR T790M Mutation.Semantic proximity Read ↗

Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.Semantic proximity Read ↗

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung CancerSemantic proximity Read ↗

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.Semantic proximity Read ↗

Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients.Semantic proximity Read ↗

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.Semantic proximity Read ↗

Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.Semantic proximity Read ↗

Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?Semantic proximity Read ↗

Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue.Semantic proximity Read ↗

[New biopsy at lung cancer progression: rational treatment of resistant lung cancer].Semantic proximity Read ↗

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Semantic proximity Read ↗

T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.